Knockdown of copper chaperone antioxidant-1 by RNA interference inhibits copper-stimulated proliferation of non-small cell lung carcinoma cells

Cai,Huawei; Peng,Fangyu

doi:10.3892/or.2013.2436

Knockdown of copper chaperone antioxidant-1 by RNA interference inhibits copper-stimulated proliferation of non-small cell lung carcinoma cells

Authors:
- Huawei Cai
- Fangyu Peng
View Affiliations

Affiliations: Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX 75390-8542, USA
Published online on: April 29, 2013 https://doi.org/10.3892/or.2013.2436
Pages: 269-275

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Copper is required for cell proliferation and tumor angiogenesis. Cellular copper metabolism is regulated by a network of copper transporters and chaperones. Antioxidant-1 (ATOX1) is a cytosolic copper chaperone important for intracellular copper transport, which plays a role in the regulation of cell proliferation by functioning as a transcription factor in cell growth signal-transduction pathways. The present study aimed to explore the role of ATOX1 in the copper-related regulation of lung cancer cell proliferation by immunohistochemical (IHC) analysis of ATOX1 expression in non-small cell lung cancer (NSCLC) tissue samples and by assessing the effects of RNA interference (RNAi)-mediated knockdown of ATOX1 on copper-stimulated proliferation of NSCLC cells. Overexpression of ATOX1 was detected in NSCLC by IHC analysis of the tissue samples from patients diagnosed with NSCLC when compared with expression of ATOX1 in non-malignant lung tissue samples. Knockdown of ATOX1 in the NSCLC cells transduced by a lentiviral vector encoding short hairpin RNA (shRNA) specific for ATOX1 was associated with reduction in copper-stimulated cell proliferation. These findings suggest that ATOX1 plays an important role in copper-stimulated proliferation of NSCLC cells and ATOX1 holds potential as a therapeutic target for lung cancer therapy targeting copper metabolism.

View Figures

View References

1	Vander Heiden MG: Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 10:671–684. 2011.PubMed/NCBI
2	Jones NP and Schulze A: Targeting cancer metabolism - aiming at a tumor’s sweet-spot. Drug Discov Today. 17:232–241. 2012.PubMed/NCBI
3	Hamanaka RB and Chandel NS: Targeting glucose metabolism for cancer therapy. J Exp Med. 209:211–215. 2012. View Article : Google Scholar : PubMed/NCBI
4	Goldberg MS and Sharp PA: Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. J Exp Med. 209:217–224. 2011. View Article : Google Scholar : PubMed/NCBI
5	Olivares M and Uauy R: Copper as an essential nutrient. Am J Clin Nutr. 63:S791–S796. 1996.
6	Uauy R, Olivares M and Gonzalez M: Essentiality of copper in humans. Am J Clin Nutr. 67(5 Suppl): S952–S959. 1998.
7	Theophanides T and Anastassopoulou J: Copper and carcinogenesis. Crit Rev Oncol Hematol. 42:57–64. 2002. View Article : Google Scholar : PubMed/NCBI
8	Finney L, Vogt S, Fukai T and Glesne D: Copper and angiogenesis: unravelling a relationship key to cancer progression. Clin Exp Pharmacol Physiol. 36:88–94. 2008. View Article : Google Scholar : PubMed/NCBI
9	Tisato F, Marzano C, Porchia M, Pellei M and Santini C: Copper in diseases and treatments, and copper-based anticancer strategies. Med Res Rev. 30:708–749. 2010.PubMed/NCBI
10	Margalioth EJ, Schenker JG and Chevion M: Copper and zinc levels in normal and malignant tissues. Cancer. 5:868–872. 1983. View Article : Google Scholar : PubMed/NCBI
11	Diez M, Arroyo M, Cerdan FJ, Munoz M, Martin MA and Balibrea JL: Serum and tissue trace metal levels in lung cancer. Oncology. 4:230–234. 1989.PubMed/NCBI
12	Peng F, Lu X, Janisse J, Muzik O and Shields AF: PET of human prostate cancer xenografts in mice with increased uptake of ⁶⁴CuCl₂. J Nucl Med. 47:1649–1652. 2006.PubMed/NCBI
13	Zhang H, Cai H, Lu X, Muzik O and Peng F: Positron emission tomography of human hepatocellular carcinoma xenografts in mice using copper (II)-64 chloride as a tracer. Acad Radiol. 18:1561–1568. 2011. View Article : Google Scholar
14	Puig S and Thiele DJ: Molecular mechanisms of copper uptake and distribution. Curr Opin Chem Biol. 6:171–180. 2002. View Article : Google Scholar : PubMed/NCBI
15	Lutsenko S: Human copper homeostasis: a network of interconnected pathways. Curr Opin Chem Biol. 14:211–217. 2010. View Article : Google Scholar : PubMed/NCBI
16	Klomp LW, Lin SJ, Yuan DS, Klausner RD, Culotta VC and Gitlin JD: Identification and functional expression of HAH1, a novel human gene involved in copper homeostasis. J Biol Chem. 272:9221–9226. 1997. View Article : Google Scholar : PubMed/NCBI
17	Culotta VC, Klomp LW, Strain J, Casareno RL, Krems B and Gitlin JD: The copper chaperone for superoxide dismutase. J Biol Chem. 272:23469–23472. 1997. View Article : Google Scholar : PubMed/NCBI
18	Rae TD, Schmidt PJ, Pufahl RA, Culotta VC and O’Halloran TV: Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase. Science. 284:805–808. 1999. View Article : Google Scholar : PubMed/NCBI
19	Punter FA, Adams DL and Glerum DM: Characterization and localization of human COX17, a gene involved in mitochondrial copper transport. Hum Genet. 107:69–74. 2000. View Article : Google Scholar : PubMed/NCBI
20	Suzuki C, Daigo Y, Kikuchi T, Katagiri T and Nakamura Y: Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res. 63:7038–7041. 2003.PubMed/NCBI
21	Itoh S, Kim HW, Nakagawa O, Ozumi K, Lessner SM, Aoki H, et al: Novel role of antioxidant-1 (Atox1) as a copper-dependent transcription factor involved in cell proliferation. J Biol Chem. 283:9158–9167. 2008. View Article : Google Scholar : PubMed/NCBI
22	Muller PA and Klomp LW: ATOX1: a novel copper-responsive transcription factor in mammals? Int J Biochem Cell Biol. 41:1233–1236. 2009. View Article : Google Scholar : PubMed/NCBI
23	Sui G, Soohoo C, Affar EB, Gay F, Forrester WC and Shi Y: A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci USA. 99:5515–5520. 2002. View Article : Google Scholar : PubMed/NCBI
24	Brummelkamp TR, Bernards R and Agami R: Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell. 2:243–247. 2002. View Article : Google Scholar : PubMed/NCBI
25	Zhang H, Ronald Thomas R, Oupicky D and Peng F: Synthesis and characterization of new copper thiosemicarbazone complexes with an ONNS quadridentate system: cell growth inhibition, S-phase cell cycle arrest and proapoptotic activities in the cisplatin-resistant neuroblastoma cells. J Biol Inorg Chem. 13:47–55. 2008. View Article : Google Scholar
26	Qiu Q, Jiang JY, Bell M, Tsang BK and Gruslin A: Activation of endoproteolytic processing of insulin-like growth factor-II in fetal, early postnatal, and pregnant rats and persistence of circulating levels in postnatal life. Endocrinology. 148:4803–4811. 2007. View Article : Google Scholar : PubMed/NCBI
27	van de Loosdrecht AA, Beelen RH, Ossenkoppele GJ, Broekhoven MG and Langenhuijsen MM: A tetrazolium-based colorimetric MTT assay to quantitate human monocyte mediated cytotoxicity against leukemic cells from cell lines and patients with acute myeloid leukemia. J Immunol Methods. 174:311–320. 1994.
28	Mangala LS, Zuzel V, Schmandt R, Leshane ES, Halder JB, Armaiz-Pena GN, et al: Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res. 15:3770–3780. 2009. View Article : Google Scholar : PubMed/NCBI
29	Cheung BB and Marshall GM: Targeting ATP7A to increase the sensitivity of neuroblastoma cells to retinoid therapy. Curr Cancer Drug Targets. 11:826–836. 2011. View Article : Google Scholar : PubMed/NCBI